11. Segment Information Segment Reporting

6 Months Ended

Jun. 30, 2020

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

SEGMENT INFORMATION

Information regarding operating segments for the three months ended June 30, 2020 and 2019 is as follows (in millions):

		Life Science		Clinical Diagnostics		Other Operations
Segment net sales	2020	$	252.1	$	283.2	$	1.6
	2019	$	212.4	$	357.1	$	3.1
Segment net profit (loss)	2020	$	32.7	$	16.6	$	(0.1)
	2019	$	11.4	$	42.4	$	(0.5)

Information regarding operating segments for the six months ended June 30, 2020 and 2019 is as follows (in millions):

		Life Science		Clinical Diagnostics		Other Operations
Segment net sales	2020	$	479.2	$	623.4	$	5.9
	2019	$	428.1	$	691.1	$	7.4
Segment net profit (loss)	2020	$	58.0	$	62.8	$	0.7
	2019	$	34.3	$	73.2	$	(0.6)

Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance.  Net corporate operating and other expense for segment results consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker.  Interest expense is charged to segments based on the carrying amount of inventory and receivables employed by that segment. The following reconciles total segment profit to consolidated income before income taxes (in millions):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2020		2019		2020		2019
Total segment profit	$	49.2	$	53.3	$	121.5	$	106.9
Foreign currency exchange losses, net	(0.8)		(1.2)		(1.7)		(2.5)
Net corporate operating and other expense not allocated to segments	(3.2)		(2.8)		(6.9)		(5.7)
Change in fair market value of equity securities	1,183.5		716.4		2,011.2		1,775.6
Other income (expense), net	17.2		3.9		20.5		22.6
Consolidated income before income taxes	$	1,245.9	$	769.6	$	2,144.6	$	1,896.9